Glaukos Corporation (GKOS) Revenue by Segment
Glaukos revenue by segment at a glance
In Q2 fiscal 2026 (the quarter ended June 30, 2026), Glaukos's largest product or service was Glaucoma, with $155.18 million or 84% of revenue, up 49.9% from a year earlier. Next: Corneal Health (16%).
By region, United States brought in 79% and Non-US brought in 21% of revenue in Q2 fiscal 2026.
By country, UNITED STATES brought in 79% and Non-US brought in 21% of revenue in Q2 fiscal 2026.
The fastest-growing product or service from a year earlier was Glaucoma (+49.9%).
From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.
Glaukos Corporation
Revenue breakdown
Fiscal quarters, from company filings
Glaukos revenue by product or service, last 4 quarters
| Product or service | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| Glaucoma | $155.2M | $129.3M | $110.2M | $103.5M | 84% |
| Corneal Health | $30.4M | $21.3M | $23.3M | $20.6M | 16% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Glaukos revenue by region, last 4 quarters
| Region | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| United States | $146.7M | $112.3M | $101.5M | $90.5M | 79% |
| Non-US | $38.9M | $38.2M | $32.1M | $33.6M | 21% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Glaukos revenue by country, last 4 quarters
| Country | Q2 FY26 | Q1 FY26 | Q3 FY25 | Q2 FY25 | Share |
|---|---|---|---|---|---|
| UNITED STATES | $146.7M | $112.3M | $101.5M | $90.5M | 79% |
| Non-US | $38.9M | $38.2M | $32.1M | $33.6M | 21% |
In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.
Questions and answers
Which product or service makes the most money for Glaukos?
Glaucoma: $155.18 million, or 84% of revenue, in Q2 fiscal 2026.
What are Glaukos's main products and services?
By revenue in Q2 fiscal 2026: Glaucoma (84%) and Corneal Health (16%).
Where does Glaukos make its money?
By region in Q2 fiscal 2026: United States (79%) and Non-US (21%).
